Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
38080
CAS Number:
366017-09-6
Mubritinib
Purity:
≥ 98 % (HPLC)
Synonym(s):
( E )-4-[[4-[4-(1 H -1,2,3-triazol-1-yl)butyl]phénoxy]méthyl]-2-[4-(trifluorométhyl)styryl]oxazole, TAK 165
Documents
$287.83 /25 mg
Taille
Request Bulk Quote
Informations sur le produit

Mubritinib is an innovative compound recognized for its potential in targeted cancer therapies, particularly in the treatment of various malignancies. This small molecule inhibitor is designed to selectively target specific kinases, making it a valuable asset in precision medicine. Its unique structure, featuring a triazole moiety and a trifluoromethylphenyl group, enhances its binding affinity and specificity, which can lead to improved therapeutic outcomes. Researchers have noted its effectiveness in inhibiting tumor growth and promoting apoptosis in cancer cells, making it a promising candidate for further clinical development.

Mubritinib's applications extend beyond oncology; it is also being explored in the fields of immunology and neurology, where its ability to modulate cellular pathways may offer new avenues for treatment. The compound's favorable pharmacokinetic properties, including its solubility and bioavailability, further support its potential in drug formulation. As the scientific community continues to investigate its full capabilities, Mubritinib stands out as a significant advancement in the search for effective cancer therapies and beyond.

Numéro CAS 
366017-09-6
Formule moléculaire
C 25 H 23 F 3 N 4 O 2
Poids moléculaire 
468.48
Point de fusion 
158 - 162 °C
Informations générales
Numéro CAS 
366017-09-6
Formule moléculaire
C 25 H 23 F 3 N 4 O 2
Poids moléculaire 
468.48
Point de fusion 
158 - 162 °C
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Mubritinib is widely utilized in research focused on:

  • Cancer Treatment: Primarily developed for treating certain types of cancer, particularly those with specific genetic mutations. It targets the BTK (Bruton’s tyrosine kinase) pathway, which is crucial for the survival of malignant B cells.
  • Clinical Trials: Actively involved in clinical trials, providing researchers with valuable data on its efficacy and safety for patients with hematological malignancies, enhancing the understanding of targeted therapies.
  • Combination Therapies: Investigated for use in combination with other cancer therapies, potentially improving treatment outcomes and reducing resistance in patients who have not responded to standard treatments.
  • Pharmaceutical Development: Used in the development of new formulations and delivery methods, allowing for more effective dosing regimens and improved patient compliance.
  • Personalized Medicine: Plays a role in the growing field of personalized medicine, where treatments are tailored based on individual genetic profiles, ensuring that patients receive the most effective therapies for their specific conditions.

Citations